Clinico-pathological prognostic factors in hematogenously disseminated colorectal cancer

Background: Ekberg`s criteria for liver resections (LR) of colorectal cancer liver metastases (CRCLM) have been accepted as a `dogma` and the procedure - as a `gold standard` since 1986. There are many wellknown predictive factors for the early and long-term results in this field of surgery. However, some of them are still a matter of debate.Aim: Study on the possible prognostic value of some clinical-pathological factors for the early and late results after major LR (≥ 2 segments) of CRCLM.Material and methods: A total of 143 radical (R0) major LR (≥ 2 segments) of synchronous and metachronous CRCLM were performed between 01.01.20007 - 31.12.2014 in the Clinic of Liver, Biliary, Pancreatic and General Surgery, Tokuda Hospital Sofia. The design of the study was `a single center` and `retrospective`. We analyzed the data with possible predictive value - demography, comorbidity, liver function, ASA group, neoadjuvant chemotherapy, type and characteristics of the surgical procedure, pathological data (T,N,G,H) and time of detection of metastases (synchronous or metachronous). The early postoperative morbidity and mortality rates were compared with these factors looking for correlation. The long-term follow-up period was ≥ 12 months for 86 patients (60.1%).Results: The early postoperative mortality rate was 2.8% (4 cases) for the whole series. The specific morbidity rates were significantly higher in patients above 65 years of age, with ≥ 3 comorbid conditions, multivisceral resections in cases of synchronous metastases and atypical (non-anatomical) LR. The majority of CRCLM cases were ≥ Т2, N (+) positive and G2-3. Unfavorable prognostic factors were the detection of metachronous lesions earlier than 12 months after a curative previous resection especially on the basis of adequate chemotherapy.Conclusions: The knowledge on prognostic factors in patients with CRCLM as well as on indications and contraindications helps the correct preoperative judgment on choosing the right and appropriate type and volume of surgical procedures

Comparative analyses between the early postoperative results after major liver resections of colorectal and noncolorectal cancer liver metastases

Background: Liver resections (LR) are an obligatory element in the multimodal treatment scheme of colorectal cancer liver metastases (CRCLM). Nowadays still there are debates about the benefit of any aggressive surgical approach in noncolorectal cancer liver metastases (NCRCLM) because many authors report desperately high rates of early specific post-resection complications (SPRC) followed by unsatisfactory long term results.Aim: Comparative analyses between the SPRC after major liver resections (MLR), i.e. ≥ 2 segments of CRCLM and NCRCLM for confirming or denying the hypothesis of higher risk in the group of NCRLM.Material and methods: A total of 331 MLR of benign and malignant tumors were performed between 01.01.2007 - 31.12.2014 in the Clinic of Liver, Biliary, Pancreatic and General Surgery, Tokuda Hospital Sofia. Radical resections received 143 CRCLM patients and 58 NCRCLM patients, both synchronous and metachronous. The design of the study was `a single center` and `retrospective`. The perioperative data of these 201 patients were analyzed and finally 59 cases of CRCLM (Group 1) and 36 cases of NCRCLM (Group 2) were included in the study. All the metastases were metachronous and no significant differences in demography, comorbidity, liver function, ASA group, neoadjuvant chemotherapy and surgery specificity were detected between the two groups. Cases that were indicated for MLR were those under 65 years of age, with preserved liver function, without serious pulmonary and cardiac concomitant diseases, and estimated as ASA group ≤ III. Data about SPRC were collected and analyzed. Results: The entire early postoperative mortality rate was 3.2% (3 fatal outcomes) - 1/59 (1.7%) in group 1 and 2/36 (5.5%) in group 2. The cause of death was liver failure, sepsis and pulmonary embolism. The rate of SPRC was significantly higher in group 2, affecting 16/36 patients (44.4%) while only 18 out of all the 59 patients (30.5%) in group 1 suffered specific complications. However only 5.1% and 8.3% of the SPRC necessitated reoperations in group 1 and group 2 respectfully. The comparative analysis denied any prognostic value for the early SPRC played by the time of metastases detection, adjuvant chemotherapy, the duration of liver resection procedure and the necessity of blood transfusion. Conclusions: Both mortality and specific morbidity after MLR affected patients with ≥3 comorbid conditions which proved to be the only predictive factor for SPRC. SPRC were more frequent in group 2 (NCRCLM) but the great majority of them were solved by conservative measures, less often by interventional procedure and reoperations were indicated very rarely

Genicular artery embolisation in patients with osteoarthritis of the knee (GENESIS 2): protocol for a double-blind randomised sham-controlled trial

Knee osteoarthritis is a leading cause of chronic disability and economic burden. In many patients who are not surgical candidates, existing treatment options are insufficient. Clinical evidence for a new treatment approach, genicular artery embolisation (GAE), is currently limited to single arm cohort, or small population randomised studies. This trial will investigate the use of a permanent embolic agent for embolisation of abnormal genicular arterial vasculature to reduce pain in patients with mild to moderate knee osteoarthritis. Up to 110 participants, 45 years or older, with knee pain for ≥ 3 months resistant to conservative treatment will be randomised (1:1) to GAE or a sham procedure. The treatment group will receive embolisation using 100-micron Embozene™ microspheres (Varian, a Siemens Healthineers Company) (investigational use for this indication in the UK), and the sham group will receive 0.9% saline in an otherwise identical procedure. Patients will be followed for 24 months. At 6 months, sham participants will be offered crossover to GAE. The primary endpoint is change of 4 Knee Injury and OA Outcome Score subscales (KOOS ) at 6 months post-randomisation. The study will also evaluate quality of life, health economics, imaging findings, and psychosocial pain outcomes. The primary manuscript will be submitted for publication after all participants complete 6 months of follow-up. The trial is expected to run for 3.5 years